Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report

被引：0
作者：
Mehmood, Faisal [1 ]
Touseef, Mumtaz [2 ]
Ashraf, Amna [2 ]
Rai, Izza Ali [3 ]
机构：
[1] Combined Mil Hosp, Dept Radiol, Lahore, Pakistan
[2] Combined Mil Hosp, Dept Med, Lahore, Pakistan
[3] Combined Mil Hosp, Dept Vasc Surg, Lahore, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期
关键词：
Hereditary breast ovarian cancer; Breast cancer; Ovarian cancer; HBOC; BRCA; PALB2; Chemotherapy; Carboplatin; Paclitaxel; PREVALENCE; MUTATIONS;
D O I：
10.47391/JPMA.20059
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like a unique case of hereditary breast-ovarian cancer syndrome (HBOC) reported in Combined Military Hospital, Lahore, Pakistan. It was marked by pathogenic variants in RAD51D, PALB2, CHEK1, and TP53 genes. Remarkably, the patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. This dynamic treatment not only led to nearly complete remission of high-grade ovarian serous cancer but also triggered regression in grade-2 invasive ductal breast cancer after just a few rounds of chemotherapy. Consequently, what started as palliative care evolved into a curative triumph.
引用
收藏
页码：2184 / 2187
页数：4
相关论文
共 50 条
  • [41] Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer
    Watanabe, M
    Aoki, Y
    Tomita, M
    Sato, T
    Takaki, Y
    Kato, N
    Kikuchi, M
    Kase, H
    Tanaka, K
    GYNECOLOGIC ONCOLOGY, 2002, 84 (02) : 335 - 338
  • [42] Acute pancreatitis induced by paclitaxel and carboplatin therapy in an ovarian cancer patient
    Shintani, D.
    Yoshida, H.
    Imai, Y.
    Fujiwara, K.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (02) : 286 - 287
  • [43] Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families
    C.F. Singer
    M.K. Tea
    G. Pristauz
    M. Hubalek
    C. Rappaport
    C.C. Riedl
    T.H. Helbich
    Wiener klinische Wochenschrift, 2015, 127 : 981 - 986
  • [44] A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
    Siddiqui, N
    Boddy, AV
    Thomas, HD
    Bailey, NP
    Robson, L
    Lind, MJ
    Calvert, AH
    BRITISH JOURNAL OF CANCER, 1997, 75 (02) : 287 - 294
  • [45] Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer
    Cong, Jianglin
    Liu, Riming
    Hou, Jianqing
    Wang, Xiuli
    Jiang, Haiyang
    Wang, Jing
    JOURNAL OF BUON, 2019, 24 (03): : 1003 - 1008
  • [46] Georgia Primary Care Providers’ Knowledge of Hereditary Breast and Ovarian Cancer Syndrome
    Navya Nair
    Cecelia Bellcross
    Lisa Haddad
    Monique Martin
    Roland Matthews
    Sheryl Gabram-Mendola
    Barbara Crane
    Dana Meaney-Delman
    Journal of Cancer Education, 2017, 32 : 119 - 124
  • [47] Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer
    Bisch, Steven P.
    Sugimoto, Akira
    Prefontaine, Michel
    Bertrand, Monique
    Gawlik, Christine
    Welch, Stephen
    McGee, Jacob
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2018, 40 (10) : 1283 - +
  • [48] Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer
    Huinink, WWT
    vanWarmerdam, LJC
    Helmerhorst, TJ
    Schaefers, MCW
    Beijnen, JH
    Rodenhuis, S
    ANNALS OF ONCOLOGY, 1997, 8 (04) : 351 - 354
  • [49] Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer
    Gordon, AN
    Asmar, L
    Messing, MJ
    Street, DG
    Pippitt, CH
    Bailey, CL
    Savage, J
    Young, JA
    GYNECOLOGIC ONCOLOGY, 2004, 94 (02) : 533 - 539
  • [50] Hereditary breast and ovarian cancer
    Lax, S. F.
    PATHOLOGE, 2017, 38 (03): : 149 - 155
12345